Metropolitan Life Insurance Company (MetLife)’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,436	Closed	-$81.4K	–	2592
2020 Q3	$81.4K	Buy	+4,436	New	+$74.6K	﹤0.01%	2338
2020 Q2	–	Sell	-4,384	Closed	-$69.4K	–	2623
2020 Q1	$69.4K	Buy	+4,384	New	+$70.8K	﹤0.01%	2254
2019 Q1	–	Sell	-4,573	Closed	-$80.8K	–	2585
2018 Q4	$80.8K	Buy	+4,573	New	+$77.7K	﹤0.01%	2407
2016 Q2	–	Sell	-8,651	Closed	-$161K	–	2702
2016 Q1	$161K	Buy	8,651 +705	+9%	+$11.7K	﹤0.01%	2300
2015 Q4	$171K	Sell	7,946 -995	-11%	-$21K	﹤0.01%	2361
2015 Q3	$151K	Buy	8,941 +78	+0.9%	+$1.94K	﹤0.01%	2469
2015 Q2	$332K	Buy	+8,863	New	+$286K	﹤0.01%	2053

Other funds holding CBMG

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CBMG Position: Q4 2020 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2020, closing a stake of 4,436 shares — an estimated $81.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CBMG in Q2 2015 and held it in 7 quarters. The position peaked at $332K in Q2 2015. 67 funds tracked by Wall St. Rank hold CBMG as of Q4 2020.

Metropolitan Life Insurance Company (MetLife) reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2020 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 4,436 Cellular Biomedicine Group, Inc. shares in Q4 2020, an estimated $81.4K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and held it in 7 quarters.
Metropolitan Life Insurance Company (MetLife)'s Cellular Biomedicine Group, Inc. position peaked at $332K in Q2 2015.
67 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2020.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2020, filed 16 Feb 2021.